`
`Case 1:20-cv-01734-UNA Document 1
`
`
`
`Filed 12/21/20 Page 1 of 36 PagelD #: 1
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF DELAWARE
`
`
`
`Ravgen, Inc.,
`
`Plaintiff, Civil Action No.
`
`V.
`
`
`
`Progenity, Inc.,
`
`
`
`JURY TRIAL DEMANDED
`
`Defendant.
`
`COMPLAINT FOR PATENT INFRINGEMENT
`
`
`
`
`
`Plaintiff Ravgen, Inc. ("Ravgen"), for its Complaint against Defendant Progenity, Inc.
`
`
`
`
`
`
`
`
`
`("Progenity"), hereby alleges as follows:
`
`NATURE OF THE ACTION
`
`1.
`
`
`
`
`
`This is a civil action for infringement of United States Patent Nos. 7,727,720 (the
`
`
`
`
`
`
`
`'"720 Patent") and 7,332,277 (the '"277 Patent") ( collectively the "Patents-in-Suit"), arising under
`
`
`
`
`
`
`
`
`
`
`
`the Patent Laws of the United States, 35 U.S.C. §§ 271 et seq.
`
`
`
`
`
`
`
`
`
`THE PARTIES
`
`
`
`2. Plaintiff Ravgen is a Delaware corporation with its principal place of business at
`
`
`
`
`
`
`
`
`
`
`
`9241 Rumsey Rd., Columbia, MD 21045. Ravgen is a pioneering diagnostics company that
`
`
`
`
`
`
`
`
`
`focuses on non-invasive prenatal testing. Ravgen has spent millions of dollars researching and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`developing novel methods for the detection of cell-free DNA to replace conventional, invasive
`
`
`
`
`
`procedures. Ravgen's innovative cell-free DNA technology has various applications, including
`
`
`
`
`
`
`
`
`
`non-invasive prenatal and other genetic testing. Those efforts have resulted in the issuance of
`
`
`
`
`
`
`
`
`
`
`
`several patents, including the Patents-in-Suit.
`
`
`
`
`
`IPR2021-01577
`
`
`Streck, Inc. v. Ravgen, Inc.
`
`
`Ravgen, lnc.'s Exhibit 2181
`
`Ex. 2181, Page 1
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 2 of 36 PagelD #: 2
`
`3.
`
`Defendant Progenity is a company organized and existing under the laws of the
`
`State of Delaware, with its principal place of business at 4330 La Jolla Village Drive, Suite 200,
`
`San Diego, California, 92122. (Ex. 5 (Progenity Inc. Form 10-Q, September 30, 2020) at 1.)
`
`Progenity has appointed Cogency Global, Inc., 850 New Burton Road, Suite 201, Dover, Delaware
`
`19904 as its agent for service of process. (Ex. 6 (Eighth Amended & Restated Certificate of
`
`Incorporation)
`
`at 1 (https ://investors.progenity. comlstatic-files/84 1 f34f1-ae3 a-4cec-a9cd-
`
`c0d58180e53e); Ex. 7 (State of Delaware Entity Status for Progenity, Inc.).)
`
`4.
`
`Progenity, itself and/or through its subsidiaries and affiliates, makes, uses, and
`
`commercializes noninvasive prenatal tests that utilize massively parallel sequencing (MPS) across
`
`the whole genome to analyze circulating cell-free DNA (cfDNA) extracted from a maternal blood
`
`sample to test for common chromosome aneuploidies, marketed under the tradename "Innatal."
`
`5.
`
`Progenity, itself and/or through its subsidiaries and affiliates, makes, uses, and
`
`commercializes noninvasive prenatal tests that apply cfDNA testing to detect common
`
`chromosomal diseases and rare monogenic diseases caused by variants in a specific gene, marketed
`
`under the tradename "Resura."
`
`6.
`
`Progenity offers and markets tests under the Innatal and Resura tradenames
`
`throughout the United States,
`
`including without limitation through the website
`
`www.progenity.com. (See generally Ex. 8 (https://www.progenity.comlproducts/innatal); Ex. 9
`
`(https://www.progenity.com/products/resura).)
`
`JURISDICTION AND VENUE
`
`7.
`
`Ravgen incorporates by reference paragraphs 1-6.
`
`2
`
`Ex. 2181, Page 2
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 3 of 36 PagelD #: 3
`
`8.
`
`This action arises under the patent laws of the United States, including 35 U.S.C.
`
`§ § 271 et seq. The jurisdiction of this Court over the subject matter of this action is proper under
`
`28 U.S.C. §§ 1331 and 1338(a).
`
`9.
`
`Venue is proper in this District pursuant to 28 U.S.C. §§ 1391(b), (c), and 1400(b).
`
`Progenity is an entity organized under the laws of Delaware and reside in Delaware for purposes
`
`of venue under 28 U.S.C. § 1400(b). Progenity conducts business in Delaware, at least by offering
`
`for sale and selling products and services through its website, which is accessible in Delaware.
`
`Progenity has also committed and continues to commit acts of infringement in this District.
`
`10.
`
`This Court has personal jurisdiction over Progenity because Progenity conducts
`
`business in Delaware by at least offering for sale or selling products and services through its
`
`website, which is accessible in Delaware, and because infringement has occurred and continues to
`
`occur in Delaware.
`
`11.
`
`Personal jurisdiction also exists over Progenity because it is an entity organized
`
`under the laws of Delaware.
`
`BACKGROUND OF THE INVENTION
`
`12.
`
`Dr. Ravinder S. Dhallan is the founder of Ravgen, Inc. and the inventor of several
`
`patents in the field of detection of genetic disorders, including chromosomal abnormalities and
`
`mutations. Ravgen's mission is to provide state of the art genetic testing that will enrich the lives
`
`of its patients. For example, through the use of its novel techniques in non-invasive prenatal
`
`diagnostic testing, Ravgen gives patients the knowledge they need to prepare for their pregnancies
`
`and treat diseases at an early stage.
`
`13.
`
`Prior to founding Ravgen, Dr. Dhallan was a board-certified emergency room
`
`physician. Between starting medical school at Johns Hopkins University and shortly after his
`
`3
`
`Ex. 2181, Page 3
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 4 of 36 PagelD #: 4
`
`residency at Mass General (Harvard University School of Medicine), Dr. Dhallan and his wife
`
`suffered three miscarriages. At that time, the prenatal diagnostic testing procedures available
`
`included (a) non-invasive techniques with low sensitivity and specificity, and (b) tests with higher
`
`sensitivity and specificity that were highly invasive and therefore associated with a risk for loss of
`
`pregnancy. After discovering the limitations on the available techniques for prenatal testing, Dr.
`
`Dhallan made it his mission to invent an improved prenatal diagnostic exam—one that was both
`
`non-invasive and accurate. In September of 2000, Dr. Dhallan founded Ravgen (which stands for
`
`"Rapid Analysis of Variations in the GENome") to pursue that goal.
`
`14.
`
`Prior to Ravgen's inventions, scientists had recognized the need for a genetic testing
`
`technique that used "cell-free" or "free" fetal DNA circulating in maternal blood. A technique that
`
`relied on circulating free fetal DNA would require only a simple blood draw from the mother and
`
`would therefore be an improvement over invasive diagnostic tests.
`
`15.
`
`However, at that time, the use of free fetal DNA for detecting chromosomal
`
`abnormalities was limited by the low percentage of free fetal DNA that could be recovered from a
`
`sample of maternal blood using existing techniques. (See, e.g., Ex. 10 (Y.M. Dennis Lo et al.,
`
`Presence cf Fetal DNA in Maternal Plasma and Serum, 350 THE LANCET 768-75 (1997),
`
`https://doi.org/10.1016/50140-6736(97)02174-0).) Dr. Dhallan recognized that a method that
`
`could increase the percentage of free fetal DNA relative to the free maternal DNA in a sample was
`
`necessary to the development of an accurate, non-invasive prenatal diagnostic test.
`
`16.
`
`After substantial research, Dr. Dhallan conceived that including an agent that
`
`impedes cell lysis (disruption of the cell membrane) if cells are present during sample collection,
`
`shipping, handling, and processing would permit the recovery of a larger percentage of cell-free
`
`fetal DNA (relative to the cell-free maternal DNA in a sample). Dr. Dhallan hypothesized that
`
`4
`
`Ex. 2181, Page 4
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 5 of 36 PagelD #: 5
`
`this new approach would decrease the amount of maternal cell lysis and therefore lower the amount
`
`of cell-free maternal DNA in the sample, thereby increasing the percentage of cell-free fetal DNA.
`
`He developed a novel method for processing cell-free fetal DNA that involved the addition of an
`
`agent that impedes cell lysis—for example, a membrane stabilizer, a cross-linker, and/or a cell
`
`lysis inhibitor—to maternal blood samples coupled with careful processing protocols. With that
`
`novel method, Dr. Dhallan was able to increase the relative percentage of cell-free fetal DNA in
`
`the processed sample.
`
`17.
`
`Having successfully increased the relative percentage of cell-free fetal DNA
`
`recovered, Dr. Dhallan next addressed the challenge of distinguishing between the cell-free
`
`maternal and cell-free fetal DNA in a sample in order to determine whether a chromosomal
`
`abnormality is present in the fetal DNA. Prior to Ravgen' s inventions, known methods for
`
`detecting fetal chromosomal abnormalities were time-consuming and burdensome. Many required
`
`amplification of the entire sequence of a gene, or quantification of the total amount of a particular
`
`gene product in a sample. Dr. Dhallan developed an alternate method that greatly increased the
`
`efficiency of this process by taking advantage of the variation of base sequences among different
`
`individuals (including a mother and fetus) ("alleles") at particular positions ("loci") on
`
`chromosomes. The term "allele" refers to an alternate form of a gene, or a non-coding region of
`
`DNA that occurs at a particular locus on a chromosome. The alleles present at certain loci on
`
`chromosomes (including, for example, "single nucleotide polymorphisms" or "SNPs") vary
`
`between different individuals. At such a locus, a fetus may therefore inherit an allele from its
`
`father that differs from the alleles present at that locus on its mother's chromosome. Dr. Dhallan
`
`developed a novel method for quantifying the allelic ratio at such a locus (or loci) of interest in a
`
`sample comprising maternal and fetal cell-free DNA in order to detect whether a fetal
`
`5
`
`Ex. 2181, Page 5
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 6 of 36 PagelD #: 6
`
`chromosomal abnormality was present in the fetal DNA of the sample, without requiring physical
`
`separation of the fetal from the maternal cell-free DNA.
`
`18.
`
`Dr. Dhallan understood that his breakthroughs laid the foundation for the
`
`development of accurate non-invasive prenatal diagnostic tests. For example, he published a paper
`
`in the Journal cf the American Medical Association (JAMA) in 2004, explaining that "the methods
`
`described herein for increasing the percentage of cell-free fetal DNA provide a solid foundation
`
`for the development of a noninvasive prenatal diagnostic test." (Ex. 11 at 1119 (R. Dhallan et al.,
`
`Methods to Increase the Percentage cfFree Fetal DNA Recoveredfrom the Maternal Circulation,
`
`291 JAMA 1114-19 (2004), https://doi.org/10.loolijama.291.9.1114).)
`
`19.
`
`JAMA also ran an editorial alongside Dr. Dhallan's article in 2004, recognizing the
`
`significance of his inventions to applications in prenatal genetic diagnosis and cancer detection
`
`and surveillance:
`
`In this issue of THE JOURNAL, the findings reported in the study
`by Dhallan and colleagues on enhancing recovery of cell-free DNA
`in maternal blood have major clinical implications. Developing a
`reliable, transportable technology for cell-free DNA analysis
`impacts 2 crucial areas—prenatal genetic diagnosis and cancer
`detection and surveillance. In prenatal genetic diagnosis, detecting
`a fetal abnormality without an invasive procedure (or with fewer
`invasive procedures) is a major advantage. Likewise in cancer
`surveillance (eg, in patients with leukemia), monitoring treatment
`without having to perform a bone marrow aspiration for karyotype
`also would be of great benefit.
`
`With prospective studies focusing on clinical applications of these
`findings, profound clinical implications could emerge for prenatal
`diagnosis and cancer surveillance.
`
`(Ex. 12 at 1135, 1137 (J.L. Simpson & F. Bischoff, Cell-Free Fetal DNA in Maternal Blood.
`
`Evolving
`
`Clinical
`
`Applications,
`
`291
`
`JAMA
`
`1135-37
`
`(2004),
`
`https://doi.org/10. 1001/jama.291 .9.1135).)
`
`6
`
`Ex. 2181, Page 6
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 7 of 36 PagelD #: 7
`
`20.
`
`In 2007, Dr. Dhallan published a second journal article in The Lancet that presented
`
`a study showcasing Ravgen's ability to use its novel technology to detect Down's syndrome using
`
`free fetal DNA in a maternal blood sample. (Ex. 13 (R. Dhallan et al., A Non-Invasive Test for
`
`Prenatal Diagnosis Based on Fetal DNA Present in Maternal Blood. A Preliminary Study, 369
`
`THE LANCET 474-81(2007), https://doi.org/10.1016/SO140-6736(07)60115-9).) Dr. Dhallan's
`
`peers at The Lancet also recognized that his innovative test "opens a new era in prenatal screening."
`
`(See Ex. 14 (A. Benachi & J.M. Costa, Non-Invasive Prenatal Diagnosis cf Fetal Aneiploidies,
`
`369 THE LANCET 440-42 (2007), https://doi.org/l0.1016/SO140-6736(07)60116-0).)
`
`21.
`
`Dr. Dhallan's publications received worldwide press coverage, from outlets such
`
`as CNN, BBC, and Washington Post. (See Ex. 15 (L. Palmer, A Better Prenatal Test?, CNN
`
`MONEY (Sept.
`
`12,
`
`2007),
`
`https://money.cnn.com/2007/09/07/smbusiness/amniocentesis
`
`.fsb/index.htm); Ex. 16 (Hcpe for Scfe Prenatal Gene Test, BBC NEWS, Feb 2, 2007,
`
`http://news.bbc.co.uk/2/hi/health16320273.stm); Ex. 17 (A. Gardner, Eperimental Prenatal Test
`
`Helps Spot Birth Thfects, WASH. POST (Feb. 2, 2007), https://www.washingtonpost.comlwp-
`
`dynlcontent/article/2007/02/02/AR20070202009 14 .html).)
`
`22.
`
`The Patents-in-Suit resulted from Dr. Dhallan's years-long research at Ravgen to
`
`develop these innovative new methods for detecting genetic disorders.
`
`PATENTS-IN-SUIT
`
`23.
`
`Ravgen incorporates by reference paragraphs 1-22.
`
`24.
`
`The '277 Patent, entitled "Methods For Detection Of Genetic Disorders," was duly
`
`and legally issued by the United States Patent and Trademark Office on February 19, 2008. The
`
`inventor of the patent is Ravinder S. Dhallan, and the patent is assigned to Ravgen. A copy of the
`
`'277 Patent is attached hereto as Exhibit 1.
`
`7
`
`Ex. 2181, Page 7
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 8 of 36 PagelD #: 8
`
`25.
`
`Ravgen is the exclusive owner of all rights, title, and interest in the '277 Patent, and
`
`has the right to bring this suit to recover damages for any current or past infringement of the '277
`
`Patent. (See Ex. 3.)
`
`26.
`
`The '720 Patent, entitled "Methods For Detection Of Genetic Disorders," was duly
`
`and legally issued by the United States Patent and Trademark Office on June 1, 2010. The inventor
`
`of the patent is Ravinder S. Dhallan, and the patent is assigned to Ravgen. A copy of the '720
`
`Patent is attached hereto as Exhibit 2.
`
`27.
`
`Ravgen is the exclusive owner of all rights, title, and interest in the '720 Patent, and
`
`has the right to bring this suit to recover damages for any current or past infringement of the '720
`
`Patent. (See Ex. 4.)
`
`28.
`
`The '277 Patent is directed to, among other things, novel methods used in the
`
`detection of genetic disorders. For example, claim 81 of the '277 Patent recites:
`
`A method for preparing a sample for analysis comprising isolating
`free fetal nucleic acid from a the sample, wherein said sample
`comprises an agent that inhibits lysis of cells, if cells are present,
`and wherein said agent is selected from the group consisting of
`membrane stabilizer, cross-linker, and cell lysis inhibitor.
`
`29.
`
`The '720 Patent is directed to novel methods for detecting a free nucleic acid in a
`
`sample. For example, claim 1 of the '720 Patent recites:
`
`A method for detecting a free nucleic acid, wherein said method
`comprises: (a) isolating free nucleic acid from a non-cellular
`fraction of a sample, wherein said sample comprises an agent that
`impedes cell lysis, if cells are present, and wherein said agent is
`selected from the group consisting of membrane stabilizer, cross-
`linker, and cell lysis inhibitor; and (b) detecting the presence or
`absence of the free nucleic acid.
`
`30.
`
`The Patents-in-Suit are directed to unconventional, non-routine techniques for
`
`preparing and analyzing extracellular circulatory DNA, including for the detection of genetic
`
`8
`
`Ex. 2181, Page 8
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 9 of 36 PagelD #: 9
`
`disorders. The Patents-in-Suit explain that, inter alia, the inventions claimed therein overcame
`
`problems in the field—for example, that the low percentage of fetal DNA in maternal plasma
`
`makes using the DNA for genotyping the fetus difficult—with a novel and innovative solution—
`
`the addition of cell lysis inhibitors, cell membrane stabilizers or cross-linkers to the maternal blood
`
`sample, which increase the percentage of cell-free DNA available for detection and analysis:
`
`The percentage of fetal DNA in maternal plasma is between 0.39-
`11.9% (Pertl, and Bianchi, Obstetrics and Gynecology 98: 483-490
`(2001)). The majority of the DNA in the plasma sample is
`maternal, which makes using the DNA for genotyping the fetus
`difficult. However, methods that increase the percentage of fetal
`DNA in the maternal plasma allow the sequence of the fetal DNA
`to be determined, and allow for the detection of genetic disorders
`including mutations, insertions, deletions, and chromosomal
`abnormalities. The addition of cell lysis inhibitors, cell membrane
`stabilizers or cross-linkers to the maternal blood sample can
`increase the relative percentage of fetal DNA. While lysis of both
`maternal and fetal cells is inhibited, the vast majority of cells are
`maternal, and thus by reducing the lysis of maternal cells, there is a
`relative increase in the percentage of free fetal DNA.
`
`(Ex. 1 ('277 Patent) at 32:24-39; Ex. 2 ('720 Patent) at 33:31-46 (emphases added).)
`
`31.
`
`The Patents-in-Suit teach that the benefit of Dr. Dhallan's discovery, an increase in
`
`the relative percentage of cell-free DNA, is realized by performance of the claimed method,
`
`including through the inclusion of an agent that inhibits the lysis of the cells in a sample:
`
`An overall increase in fetal DNA was achieved by reducing the
`maternal cell lysis, and thus, reducing the amount of maternal DNA
`present in the sample. In this example, formaldehyde was used to
`prevent lysis of the cells, however any agent that prevents the lysis
`of cells or increases the structural integrity of the cells can be used.
`Two or more than two cell lysis inhibitors can be used. The increase
`in fetal DNA in the maternal plasma allows the sequence of the fetal
`DNA to be determined, and provides for the rapid detection of
`abnormal DNA sequences or chromosomal abnormalities including
`but not limited to point mutation, reading frame shift, transition,
`transversion, addition, insertion, deletion, addition-deletion, frame-
`shift, missense, reverse mutation, and microsatellite alteration,
`trisomy,
`monosomy,
`other
`aneuploidies,
`amplification,
`
`9
`
`Ex. 2181, Page 9
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 10 of 36 PagelD #: 10
`
`rearrangement, translocation, transversion, deletion, addition,
`amplification, fragment, translocation, and rearrangement.
`
`(Ex. 1 ('277 Patent) at 91:44-60; Ex. 2 ('720 Patent) at 92:10-26.)
`
`32.
`
`For example, during the prosecution of the '720 Patent at the Patent and Trademark
`
`Office, Ravgen explained that the innovative concept of using agents that inhibit cell lysis during
`
`cell-free DNA detection and analysis is recited by the claimed methods of the '720 Patent,
`
`including in claim 1:
`
`Applicant has discovered that the addition of a cell lysis inhibitor to
`a sample prior to detecting the presence of free nucleic acid can
`sign Jicant!y and unepected!y increase the proportion of free
`nucleic acid obtained from the non-cellular fraction of a sample.
`
`The methods disclosed in claims 1-8, 21-23, and 26 serve a long-felt
`need in the medical community, and provide unexpected results, and
`are therefore non-obvious.
`
`(Ex. 18 ('720 File History, June 2, 2009 Response to Office Action) at 12, 14 (emphasis added).)
`
`33.
`
`The inventive concept of the Patents-in-Suit of including an agent that inhibits cell
`
`lysis—for example, a membrane stabilizer, a cross-linker, and/or a cell lysis inhibitor—with a
`
`sample represented a significant improvement in the preparation of samples used for non-invasive
`
`testing, including non-invasive prenatal testing to unmask previously undetectable fetal genetic
`
`traits. At the time of the invention, it would not have been routine or conventional to add an agent
`
`that inhibits cell lysis to a sample to increase the proportion of free nucleic acid obtained from the
`
`non-cellular fraction of a sample. In fact, as described above, that inventive concept was
`
`recognized by Dr. Dhallan's peers as "an important step in improving detection of cell-free DNA."
`
`(Ex. 12 at 1137.)
`
`34.
`
`The '277 Patent is further directed to an unconventional, non-routine method of
`
`detecting fetal chromosomal abnormalities which involves "quantitating a ratio of the relative
`
`10
`
`Ex. 2181, Page 10
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 11 of 36 PagelD #: 11
`
`amount of alleles in a mixture of maternal DNA and fetal DNA." (Ex. 19 ('277 File History, May
`
`30, 2007 Response to Office Action) at 30.) For example, claim 1 of the '277 Patent recites:
`
`A method for detecting the presence or absence of a fetal
`chromosomal abnormality, said method comprising: quantitating a
`ratio of the relative amounts of alleles at a heterozygous locus of
`interest in a mixture of template DNA, wherein said mixture
`comprises maternal DNA and fetal DNA, and wherein said mixture
`of maternal DNA and fetal DNA has been obtained from a sample
`from a pregnant female, and further wherein said heterozygous locus
`of interest has been identified by determining the sequence of alleles
`at the locus of interest, and wherein said ratio indicates the presence
`or absence of a fetal chromosomal abnormality.
`
`35.
`
`The '277 Patent explains that this claimed method represented a significant
`
`improvement over prior art methods of detecting fetal chromosomal abnormalities, many of which
`
`were costly, time-consuming, and burdensome because they either required the amplification of
`
`the entire sequence of a gene, or quantification of the total amount of a particular gene product.
`
`(Ex. 1 at 66:14-20.) By contrast, the claimed "ratio" method of the '277 Patent only requires
`
`sequencing of discrete "loci of interest" (such as "single nucleotide polymorphisms," or "SNPs")
`
`from the collected DNA sample. (id. at 34:63-35:37 ("In fact, it is an advantage of the invention
`
`that primers that copy an entire gene sequence need not be utilized. . . . There is no advantage to
`
`sequencing the entire gene as this can increase cost and delay results. Sequencing only the desired
`
`bases or loci of interest maximizes the overall efficiency of the method because it allows for the
`
`sequence of the maximum number of loci of interest to be determined in the fastest amount of time
`
`and with minimal cost."); Id. at 35:28-37.)
`
`36.
`
`During the prosecution of the '277 Patent at the Patent and Trademark Office,
`
`Ravgen gave the following example of an implementation of the claimed "ratio" method:
`
`Applicants have invented a method for detecting the presence or
`absence of a fetal chromosomal abnormality, wherein the method
`
`11
`
`Ex. 2181, Page 11
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 12 of 36 PagelD #: 12
`
`comprises, inter alia, quantitating a ratio of the relative amount of
`alleles in a mixture of maternal DNA and fetal DNA.
`
`[R]atios were calculated at both chromosomes 13 and 21 in a
`heterogeneous mixture of 75% Down syndrome DNA and 25%
`maternal DNA. Single nucleotide polymorphisms were analyzed
`wherein the maternal genome was homozygous for one allele at a
`specific genetic site and the Down syndrome DNA was
`heterozygous at the same genetic site. If at a certain site, the
`maternal genome contains an adenine at both copies of chromosome
`13, and the Down syndrome genome is comprised of one
`chromosome with an adenine nucleotide and one chromosome with
`a guanine nucleotide, then the ratio of G:A is 0.60 (0.75 (Down
`syndrome G allele)/(0.75 Down syndrome A allele + 0.25 + 0.25
`maternal A alleles).
`
`On the other hand, if at a certain genetic site on chromosome 21, the
`maternal genome contains an adenine at both copies of chromosome
`21, and the Down syndrome genome is comprised of two
`chromosome with an adenine nucleotide and one chromosome with
`a guanine nucleotide, then the ratio of G:A is 0.375 (0.75 (Down
`syndrome G allele)/(0.75 Down syndrome A allele + 0.75 Down
`syndrome A allele + 0.25 + 0.25 (maternal A alleles). Thus, the
`methods described in the present application detect chromosomal
`abnormalities using a method that comprises, inter alia, quantitating
`a ratio of alleles in a heterogeneous mixture of DNA, wherein the
`ratio represents alleles from more than one individual.
`
`(Ex. 19 ('277 File History, May 30, 2007 Response to Office Action) at 30.)
`
`DEFENDANT'S INFRINGING ACTIVITIES
`
`37.
`
`Ravgen incorporates by reference paragraphs 1-36.
`
`A.
`
`The Accused Innatal Prenatal Screen
`
`38.
`
`In 2015, Progenity launched the Innatal® Prenatal Screen, a noninvasive prenatal
`
`screening test to screen for chromosome abnormalities through the analysis of cfDNA at or after
`
`10 weeks of gestation. (See Ex. 20 (Excerpt of Progenity, Inc. Prospectus, June 2020) at 120.) In
`
`2019, Progenity upgraded the Innatal Prenatal Screen with the latest sequencing technology,
`
`improved chemistry, and bioinformatics analysis. (Ex. 21 (https://investors.progenity.comlnews-
`
`12
`
`Ex. 2181, Page 12
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 13 of 36 PagelD #: 13
`
`releases/news-release-details/progenity-launches-first-commercially-available-custom-
`
`designed#::text=%C2%AB%20Back-
`
`,Progenity%201aunches%20first%20commercia11y%20avai1ab1e%2C%20custom%2Ddesigned%
`
`2C%20noninvasive,prenatal%20test%20for%20monogenic%20diseases&text=Progenity%20a1s
`
`o%20announces%20improvements%20to,across%20a11%20common%20chromosoma1%20aneu
`
`ploidies).) Progenity is currently developing the next generation Innatal Prenatal Screen (Innatal
`
`4th Generation) and anticipates a commercial launch by the end of 2021. (Ex. 20 (Excerpt of
`
`Progenity, Inc. Prospectus, June 2020) at 124.)
`
`39.
`
`The Innatal® Prenatal Screen analyzes cfDNA extracted "from a maternal blood
`
`sample to assess the pregnancy for common chromosome aneuploidies."
`
`(Ex. 22
`
`(https://www.progenity.com/products/innatal#practice).)
`
`40.
`
`The Innatal Prenatal Screen requires samples containing an agent that inhibits cell
`
`lysis. For example, Progenity lists "10 ml Streck DNA tube" as the required collection container
`
`for
`
`the
`
`Innatal® test.
`
`(See,
`
`e.g.,
`
`Ex.
`
`23
`
`at
`
`1
`
`(https://www.progenity.comlsites/default/files/PGOCRRequisitionWH-23 035-
`
`0 1eform082520.pdf);
`
`Ex.
`
`24
`
`(https://www.progenity.comlsites/default/files/PGWomensHealthSpecimenGuideWH- 16001-
`
`01092020 FINAL.pdf) (indicating that only blood collected in a 10 mL black-and-tan-top Streck
`
`tube
`
`will
`
`be
`
`accepted
`
`for
`
`the
`
`Innatal®
`
`test);
`
`Ex.
`
`25
`
`(https://www. streck. comlproducts/stabilizationlcell-free-dna-bct/) (showing that the black and tan
`
`top Streck tubes are Streck Blood Collection Tubes (BCTTM) tubes).) Providers of the Innatal
`
`Prenatal Screen also list "1 x 10mL provided cell-free DNA streck BCT tube" as a required
`
`material for specimen collection.
`
`(See, e.g., Ex. 26 at 61 (https://www.ap2.comlwp-
`
`13
`
`Ex. 2181, Page 13
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 14 of 36 PagelD #: 14
`
`content/uploads/20 17/04/2017-directory-services-digital.pdf);
`
`See
`
`also,
`
`Ex.
`
`27
`
`(https://www.wadsworth.org/progenity-inc-6) ("Specimen type: whole blood: maternal in Streck
`
`Cell-Free DNA BCT").)
`
`41.
`
`Progenity-funded scientific articles analyzing the Innatal Prenatal Screen confirm
`
`the use of Streck Blood Collection Tubes (BCTTM) tubes to collect samples for the Innatal Prenatal
`
`Screen. (See, e.g., Ex 28 (https://www.progenity.comlclinical-publications/proven-performance-
`
`prenatal-screen#innatal) (referencing Porreco et al., Evaluation cf a novel screening method for
`
`fetal aneiploidy using cell-free DNA in maternal plasma, J. MED. SCREENING (2019) as providing
`
`data supporting performance of the Innatal Prenatal Screen); Ex 29 at 4 (Porreco et al., Evaluation
`
`a novel screening method for fetal aneiploidy using cell-free DNA in maternal plasma, J. MED.
`
`SCREENING
`
`(2019),
`
`https://doi.org/10. 1177%2F0969 141319873682)
`
`("Venous
`
`blood
`
`(approximately 20 mL) was collected from study participants in a cell-free BCT tube (Streck.
`
`Omaha, AE, USA). Sample tubes were shipped directly to Progenity, Inc. for processing and
`
`storage within five days of collection.") (funded by Progenity).)
`
`42.
`
`The Streck Cell-Free DNA Blood Collection Tube ("BCT") includes an agent that
`
`inhibits cell lysis. A Streck Cell-Free DNA BCT "stabilizes nucleated blood cells. The unique
`
`preservative limits the release 6f genomic DIVA, allowing isolation 6f high-quality cell-free
`
`DIVA. Cell-Free DNA BCT has also been demonstrated to minimize the degradation of circulating
`
`tumor cells (CTCs). By limiting cell lysis, the specialized chemistry provides sample integrity
`
`during storage, shipping and handling of blood samples. Cell-free DNA and gDNA are stable for
`
`up to 14 days at 6 °C to 37 °C. CTCs are stable for up to 7 days at 15 °C to 30 °C." (Ex. 25 at 2
`
`(https://www. streck. comlproducts/stabilizationlcell-free-dna-bct/)).)
`
`14
`
`Ex. 2181, Page 14
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 15 of 36 PagelD #: 15
`
`43.
`
`In processing the Innatal Prenatal Screen, Progenity isolates cell-free DNA from a
`
`sample of maternal blood collected in a Streck Cell-Free DNA BCT and then analyzes the isolated
`
`fetal cell-free DNA to detect chromosomal abnormalities as shown below:
`
`Collect your sample
`Visit your healthcare provider
`Ask your doctor if this test is right for you. Your healthcare provider will take a
`blood sample from your arm and send it
`to the Progenity laboratory.
`
`Receive your results
`Results are ready in about one week.
`Positive results mean a closer look is
`needed at your baby's DNA. Negative
`results mean that your baby is very low
`risk
`
`Review your next steps
`Get complimentary access to Progenity
`Genetic Counselors to help you and
`your healthcare provider plan your next
`steps.
`
`(Ex. 8 (https://www.progenity.com/products/innatal#basics);
`
`DNA from the placenta naturally crosses into the mother's bloodstream as a
`pregnancy progresses.
`For the test, a small sample of your blood is drawn and the DNA is analyzed to check for certain
`chromosomal disorders, which can cause serious birth defects, intellectual disability, or other
`health problems in the baby.
`
`id.; see also id. (displaying video entitled "Prepare for Lfe") at 1:22-44 ("Cell-free DNA is
`
`actually what we are looking at. Cell-free DNA from the placenta of the pregnancy. Naturally
`
`during pregnancy, DNA fragments from the placenta cross into mom's bloodstream and starting
`
`at 10 weeks gestation we can actually identify this DIVA and look at it to see would a baliy be at
`
`an
`
`increased
`
`risk
`
`for
`
`a chromosomal
`
`disorder."); Ex.
`
`22
`
`(https://www.progenity.comlproducts/innatal#practice) ("Cell-free DNA (cfDNA) is analyzed
`
`from a maternal blood sample to assess the pregnancy for common chromosome aneuploidies.
`
`The Innatal Prenatal Screen utilizes massively parallel sequencing (MPS) across the whole
`
`genome. . . . The reads are counted to determine whether the sample has extra or missing reads
`
`from a particular chromosome. . . . Fetal fraction is determined for each sample using a proprietary
`
`algorithm."); Ex. 29 at 2 ("This study aimed to detect all fetal whole chromosome abnormalities
`
`15
`
`Ex. 2181, Page 15
`
`

`

`Case 1:20-cv-01734-UNA Document 1 Filed 12/21/20 Page 16 of 36 PagelD #: 16
`
`on chromosomes 13, 16, 18, 21, X, and Y, through analysis of cfDNA in maternal blood, utilizing
`
`a novel sequence targeting approach using molecular inversion probes (MIPs)").)
`
`44.
`
`On information and belief, Progenity licenses the right to perform the Innatal
`
`Prenatal Screen to third party laboratories. For example, "a portion of [Progenity's] tests are
`
`performed by third-party CLIA certified laboratories." (Ex. 20 (Excerpt of Progenity, Inc.
`
`Prospectus, June 2020) at 33.) Progenity enters into contracts with these third-party